HOME >> BIOLOGY >> NEWS
Rimonbant shows promise in addressing multiple risk factors

Quebec City, Canada, March 9, 2004 - Results of a Phase III clinical trial (RIO-Lipids or Rimonabant In Obesity) comparing rimonabant, the first drug in a new class called Selective CB1 Blockers (or SCB1Bs), to placebo found that overweight or obese patients with untreated dyslipidemia (high triglycerides, low HDL-cholesterol) lost almost 20 lbs (8.6 kg) when treated for a year with rimonabant 20mg. Weight loss was accompanied by a decrease in waist size of 3.4 inches (9.1 cm) demonstrating a significant reduction in abdominal obesity, an independent marker for heart disease. Dramatic improvements were also seen in lipid profile with a 23% increase in HDL-cholesterol (good cholesterol) and a 15% decrease in triglycerides. Improvements in glucose tolerance and insulin levels were also observed. In another important finding, the number of patients diagnosed at baseline with metabolic syndrome,1 who were treated with rimonabant 20mg, was reduced by half. The drug was also found to be safe and well-tolerated.

Rimonabant works by inhibiting the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System), believed to play a critical role in the regulation of food intake and energy expenditure.

"While the weight loss was clinically relevant, what is truly remarkable in the RIO-Lipids study is the significant effect rimonabant had on improving associated cardiovascular risk factors," said Jean-Pierre Despr's, principal investigator for RIO-Lipids and Professor in the Department of Food Sciences and Nutrition and Medicine at Laval University, and Director of Research at the Quebec Heart Institute located at the Laval Hospital Center in Quebec City, Canada. "Rimonabant appears to have a direct effect on fat cells which may be contributing to the beneficial effects of this drug on abdominal obesity and associated risk factors. Couple this with the markedly
'"/>

Contact: Glenn Lehrman
glenn.lehrman@ketchum.com
917-533-5998
Ketchum
9-Mar-2004


Page: 1 2 3 4 5 6

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Rimonbant shows promise addressing multiple risk factors

(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... Genetics Society of America,s 27th Annual Mouse Molecular ... 2014 in Pacific Grove, California. These awards ... post doctorates and scientists from underrepresented groups into ... to encourage the participation of young scientists at ...
(Date:8/28/2014)... (Maximizing Access to Research Careers) Program has announced ... of Sports Medicine,s Conference on Integrative Physiology of ... These awards are meant to promote the ... underrepresented groups into the mainstream of the basic ... young scientists at the American College of Sports ...
(Date:8/28/2014)... in German . ... with the help of sophisticated assembly lines. Mobile assembly carriers, ... part of these assembly lines. In the case of a ... stages arranged in a precise spatial and chronological sequence, resulting ... , The creation of such an assembly line at molecular ...
Breaking Biology News(10 mins):Nanoscale assembly line 2Nanoscale assembly line 3
(Date:8/28/2014)... 2014  Next month, executives from clinical trial marketing firm ... beginning with Patient-Centered Clinical Trials 2014 , to be ... , September 4-5. Patient recruitment experts Bonnie A. ... will share insights on the benefits of employing an ... – from media to mobile apps – can be used ...
(Date:8/28/2014)... Exciting new work by a Florida State University research ... can take your temperature, emit white light, and convert ... molecule looks like a butterfly. , Biwu Ma, associate ... in the FAMU-FSU College of Engineering, created the molecule ... continued to discover that his creation has many other ...
(Date:8/28/2014)... 2014 PrimeSource Building Products, Inc., ... SoundConnect to support their communication needs ... and web conferencing platform GlobalMeet powered by SoundConnect. ... needs. SoundConnect delivers award winning “results driven” ... Products will be utilizing GlobalMeet powered by ...
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
Cached News: